Now showing items 1-2 of 2

    • Cross-genotype-reactivity of the immunodominant HCVCD8 T-cell epitope NS3-1073 

      Fytili, P.; Dalekos, G. N.; Schlaphoff, V.; Suneetha, P. V.; Sarrazin, C.; Zauner, W.; Zachou, K.; Berg, T.; Manns, M. P.; Klade, C. S.; Cornberg, M.; Wedemeyer, H. (2008)
      The HCV-specific HLA-A2-restricted NS3(1073) epitope is one of the most frequently recognized epitopes in hepatitis C. NS3(1073)-specific T-cell responses are associated with clearance of acute HCV-infection. Therefore ...
    • Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study 

      Montes, A.; Perez-Pampin, E.; Navarro-Sarabia, F.; Moreira, V.; de la Sema, A. R.; Magallares, B.; Vasilopoulos, Y.; Sarafidou, T.; Fernandez-Nebro, A.; Ordonez, M. D.; Narvaez, J.; Canete, J. D.; Marquez, A.; Pascual-Salcedo, D.; Joven, B.; Carreira, P.; Moreno-Ramos, M. J.; Caliz, R.; Ferrer, M. A.; Garcia-Portales, R.; Blanco, F. J.; Magro, C.; Raya, E.; Valor, L.; Alegre-Sancho, J. J.; Balsa, A.; Martin, J.; Plant, D.; Isaacs, J.; Morgan, A. W.; Barton, A.; Wilson, A. G.; Gomez-Reino, J. J.; Gonzalez, A.; Braggss (2015)
      Introduction: We have hypothesized that incompatibility between the G1m genotype of the patient and the G1m1 and G1m17 allotypes carried by infliximab (INX) and adalimumab (ADM) could decrease the efficacy of these anti-tumor ...